Tendencies of Growth and Spread of Squamous Cell Cancer of the Cervix

Joint Meeting ◽  
1969 ◽  
pp. 574-585
Author(s):  
K. G. Ober
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Cancer Of The Cervix

Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-α and 13-cis-retinoic acid

1996 ◽  
Vol 7 (7) ◽  
pp. 800-804 ◽  
Author(s):  
Surintip Piamsomboon ◽  
Wichai Termrungruanglert ◽  
Andrzej P Kudelka ◽  
Creighton L Edwards ◽  
Ralph S Freedman ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Interferon Α ◽  
Cancer Of The Cervix

Phase III Trial Comparing Radical Radiotherapy With and Without Cisplatin Chemotherapy in Patients With Advanced Squamous Cell Cancer of the Cervix

2002 ◽  
Vol 20 (4) ◽  
pp. 966-972 ◽  
Author(s):  
R. Pearcey ◽  
M. Brundage ◽  
P. Drouin ◽  
J. Jeffrey ◽  
D. Johnston ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Survival Rates ◽  
Progression Free Survival ◽  
Lymph Node Involvement ◽  
Phase Iii ◽  
Gynecology And Obstetrics ◽  
Significant Difference ◽  
Cancer Of The Cervix

PURPOSE: To test the hypothesis that cisplatin (CDDP) administered concurrently with standard radiotherapy (RT) would improve pelvic control and survival in patients with advanced squamous cell cancer of the cervix. PATIENTS AND METHODS: A total of 259 patients with International Federation of Gynecology and Obstetrics stage IB to IVA squamous cell cervical cancer with central disease ≥ 5 cm or histologically confirmed pelvic lymph node involvement were randomized to receive RT (external-beam RT plus brachytherapy) plus weekly CDDP chemotherapy (40 mg/m2) (arm 1) or the same RT without chemotherapy (arm 2). RESULTS: A total of 253 patients were available for analysis. Median follow-up was 82 months. No significant difference was found in progression-free survival (P = .33). No significant difference in 3- and 5-year survival rates was found (69% v 66% and 62% v 58%, respectively; P = .42). The hazard ratio for survival (arm 2 to arm 1) was 1.10 (95% confidence interval, 0.75 to 1.62). CONCLUSION: This study did not show a benefit to either pelvic control or survival by adding concurrent weekly CDDP chemotherapy in a dose of 40 mg/m2 to radical RT as given in this trial. Careful attention to RT details is important for achieving optimum outcome for patients with this disease.

Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study.

1987 ◽  
Vol 5 (11) ◽  
pp. 1791-1795 ◽  
Author(s):  
D S Alberts ◽  
R Kronmal ◽  
L H Baker ◽  
D L Stock-Novack ◽  
E A Surwit ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Mitomycin C ◽  
Phase Ii ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Response Rates ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Cancer Of The Cervix

Cisplatin has proven to be the most active single agent in the treatment of metastatic and recurrent squamous cell cancer of the cervix. In a previous southwest Oncology Group (SWOG) pilot study, the addition of cisplatin to a mitomycin-C, vincristine, and bleomycin (MVB) regimen resulted in a relatively high percentage of durable complete responses. To gain more experience with cisplatin-based chemotherapy regimens, the SWOG initiated a phase II randomized trial of cisplatin, mitomycin-C plus cisplatin (MC), and MVB plus cisplatin (MVBC) in 119 patients with advanced squamous cell cancer of the cervix and no prior chemotherapy exposure. Because of slow patient accrual early in the trial, the cisplatin arm was discontinued. Five patients were declared ineligible according to protocol criteria. The three treatment groups were relatively well matched for age, prior radiation exposure, and sites of measurable disease. The overall objective response rates for cisplatin, MC, and MVBC treated patients were 33%, 25%, and 22%, respectively. Median response durations were greater than 6 months. Median survival durations associated with cisplatin, MC, and MVBC treatment were 17.0, 7.0, and 6.9 months, respectively. There were no drug-related deaths. Severe or life-threatening leukopenia and thrombocytopenia were observed in 18% to 24% of patients treated with MVBC and MC, but in none of those receiving cisplatin alone. We conclude that the low response rates and short durations of both response and survival observed in patients randomized to the two chemotherapy combinations suggest that only enhanced toxicity was gained through the addition of mitomycin-C or MVB to cisplatin in patients with advanced cervix cancer.

Highly Differentiated Keratinizing Squamous Cell Cancer of the Cervix

2001 ◽  
Vol 25 (10) ◽  
pp. 1310-1315 ◽  
Author(s):  
Carl Morrison ◽  
Francesco Catania ◽  
Paul Wakely ◽  
Gerard J. Nuovo
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Cancer Of The Cervix

An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

1997 ◽  
Vol 8 (7) ◽  
pp. 657-661 ◽  
Author(s):  
Andrzej P Kudelka ◽  
Rodger Winn ◽  
Creighton L Edwards ◽  
G Downey ◽  
Harvey Greenberg ◽  
...  
Keyword(s):  
Phase Ii ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Phase Ii Study ◽  
Cell Cancer ◽  
Cancer Of The Cervix
Sign in / Sign up

Export Citation Format

Share Document